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Purpose. This study aimed to explore the relationship among insulin sensitivity and ectopic fat depots in participants with different
glucose status.Methods. Fifty-nine men and women were enrolled in this study: 29 with normal glucose tolerance (NGT), 17 with
impaired glucose tolerance (IGT), and 13 with type 2 diabetes mellitus (T2DM). All participants underwent a hyperinsulinemic-
euglycemic clamp to assess the insulin sensitivity index (𝑀 value) and magnetic resonance imaging to measure the hepatocellular
lipid content (HCL), skeletal muscle fat content including intramyocellular lipid (IMCL) and extramyocellular lipid (EMCL) of
tibialis anterior (ta), and soleus muscle (sol). Results. The𝑀 value of NGT group was higher than those of IGT and T2DM groups
(𝑃 = 0.001). ParticipantswithT2DMhad the highestHCL and IMCL (ta) comparedwith those inNGTand IGTgroups (𝑃 = 0.001).
The𝑀 value had an inverse relationship with HCL (𝑟 = −0.789, 𝑃 = 0.001), IMCL (sol) (𝑟 = −0.427, 𝑃 = 0.002), and IMCL (ta)
(𝑟 = −0.419, 𝑃 = 0.002). Stepwise linear regression analysis showed that HCL (standardized 𝛽 = −0.416; 𝑃 = 0.001) had an
independent relationship with𝑀 value. Conclusions. Hepatocellular lipid content deposition happens earlier than skeletal muscle
fat deposition. HCL is an independent risk factor for insulin resistance and may be used to evaluate the risk of developing T2DM
as a noninvasive marker of insulin sensitivity index.
1. Introduction
Insulin resistance leads to impaired glucose absorption,
promotes hepatic gluconeogenesis, and is associated with the
metabolic syndrome, especially with its effects on the liver
and muscle [1]. Insulin resistance promotes hydrolysis of
triglycerides and release of free fatty acids from adipose tis-
sues, reduces glucose uptake inmuscle cells, impairs glycogen
synthesis, and increases gluconeogenesis, lipogenesis, and
synthesis of CRP in the liver [2, 3].
Triglycerides in the liver and skeletal muscle promote
peripheral and hepatic insulin resistance, thereby contribut-
ing to the pathogenesis of type 2 diabetesmellitus (T2DM) [4,
5]. Diabetics have a greater muscle triglyceride (MT) content
than individuals with impaired glucose tolerance (IGT) and
normal glucose tolerance (NGT), independent of the total
body fat percentage [6]. However, some studies showed no
association between MT levels and glycemic control in obese
individuals [7]. Another study showed that MT content is
associated with hepatic, but not peripheral, insulin resistance
[4].
Studies on the relationship between insulin sensitivity
and lipid content have shown inconsistent results. Some but
not all studies have shown correlation between intramyocel-
lular lipid (IMCL) content with measurements of insulin
resistance [8–10]. Conversely, some studies have shown a
direct relationship between intrahepatic triglycerides and
IMCL in the soleusmuscle, but not the tibialis anterior [11, 12].
A relativelyminor loss of body weight (3%) was accompanied
by a major reduction in visceral fat mass (12%) and in LF
content (33%) [13].
In this study, the fat depots of liver and skeletal muscle
with insulin sensitivity were assessed in study participants,
aiming to explore the relationship between these parameters.
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2. Methods
2.1. Study Population. Between January, 2013, and August,
2014, 59 individuals (males: 30) were included in this
study: 29 with normal glucose tolerance (NGT), 17 with
impaired glucose tolerance (IGT), and 13 with type 2 diabetes
mellitus (T2DM). The participants with T2DM had the
oral hypoglycemic drugs including metformin or acarbose.
All participants underwent a hyperinsulinemic-euglycemic
clamp (𝑀 value) and magnetic resonance imaging (MRI)
to calculate hepatocellular lipid content (HCL) and 1H-
magnetic resonance spectroscopy to measure intramyocellu-
lar lipid (IMCL) and extramyocellular lipid (EMCL) of tibialis
anterior (ta) and soleus muscle (sol). The study protocol
was approved by the ethics committee at The First Affiliated
Hospital of Sun Yat-sen University, Guangzhou, China, and
all participants provided written informed consent. The
study was performed in compliance with the Declaration of
Helsinki and Good Clinical Practice.
2.2. Measurements. The weight and height of all participants
were measured to calculate the BMI (kg/m2). The waist
circumference (WC) was measured at the midpoint between
the lowest rib and the uppermost lateral border of the right
iliac crest and hip circumference (HC) was measured at
their widest point to calculate the waist-to-hip ratio (WHR).
Blood pressure was measured using a mercury sphygmo-
manometer at a resting state. All blood samples were taken
in the morning following an overnight fast of at least eight
hours. The following were measured: fasting plasma glu-
cose (FPG), 30-minute plasma glucose (PG30m), two-hour
plasma glucose (PG2 h), hemoglobin A1C (HbA1c), fasting
insulin (FINS), serum total cholesterol (CHOL), triglycerides
(TG), high-density lipoprotein cholesterol (HDL-c), low-
density lipoprotein cholesterol (LDL-c), alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), and gamma-
glutamyl transpeptidase (GGT). The estimated glomerular
filtration rate (eGFR) values were calculated from creatinine
levels using the CKD-EPI formula.
2.3. M Value, 𝛽 Cell Function, and Insulin Sensitivity. A
hyperinsulinemic-euglycemic clamp was used after an eight-
hour fast on a different day. In brief, insulin diluted in
0.9% saline was infused intravenously at a constant rate
of 80mU/m2 per minute for 2 hours. Plasma glucose was
clamped at 5.6mmol/L with a variable-rate infusion of 20%
dextrose based on the arterialized plasma glucose value,
which was measured every five minutes. The insulin levels
were maintained at 86.5 (68.5–106.2)𝜇U/mL. Peripheral
insulin sensitivity (𝑀 value) was calculated by dividing the
insulin-stimulated glucose disposal rate by the steady-state
plasma insulin concentration during the last 30 minutes of
the clamp [14].
Homeostasis model assessment of insulin resistance
(HOMA-IR) values was calculated as FPG (mmol/L) × FINS
(𝜇U/mL)/22.5. Homeostasis model assessment-𝛽 (HOMA-
𝛽) values were calculated as 20 × FINS (𝜇U/mL)/[FPG
(mmol/L) − 3.5]. Insulin activation indices (IAI) values
were calculated as 1/[FPG (mmol/L) × FINS (𝜇U/mL)].
Quantitative insulin sensitivity check index (QUICK) values
were calculated as 1/[log FPG (mg/dL) + log FINS (𝜇U/mL)].
2.4. Body Fat Composition, HCL, IMCL, and EMCL. The
body fat ratio (BFR), fat mass (FM) index, and lean mass
(LM) index were measured using human body composition
analyzer (Tanita MC-180, Japan). Electrodes were attached to
parts of the body and a small electric signal was circulated.
The impedance or resistance to the signal was measured as it
traveled through the water found in muscle and fat.
Subjects underwent an upper-abdominal coil MRI (3-
Tesla whole-body scanner; SIEMENS 3.0 T MAGNETOM
Verio) examination that involved an initial set of localizer
images and the T1 volumetric interpolated breath hold
examination (VIBE) Dixon sequence to calculate HCL [15].
All subjects were imaged in supine position and carefully
instructed to hold breath during end inspiration to ensure
consistency among subjects. The parameters of the images
were TE (echo time), 2.5ms/3.7ms and TR (repetition time),
5.47ms. Four images were generated at the same time within
a single breath hold, including in-phase and out-of-phase,
as well as fat and water phase images. HCL map was
generated by combining the MR images obtained during
both fat phase and water phase of each subject. This was
done by using a plug-in algorithm created under MATLAB
platform (MATLAB r2011b, MathWorks, American), using
the following equation: HCL = 𝐹/(𝑊 + 𝐹) ∗ 100% (𝐹: fat
volume;𝑊: water volume). Two radiologists manually placed
an irregular-shaped region of interest (RIO) covering the
entire liver in 21 consecutive slices (max-area centered) of
each patient. The mean HCL in the ROI of each subject was
recorded.
The IMCL and EMCL of tibialis anterior (ta, mixed type
I/II muscle fibers) and soleus muscle (sol, predominantly
type I fibers) were quantified using the 1H-magnetic reso-
nance spectroscopy (SIEMENS 3.0 T MAGNETOM Verio).
A single volume spectroscopy was applied, with the following
measurement parameters: TR 3000ms, TE 20ms, volume
of interest 10mm × 10mm × 10mm, and 48 acquisitions.
The water resonance was set to 4.7 ppm, IMCL resonance
was set to 1.3 ppm, and EMCL resonance was set to 1.5 ppm.
Voxel positon was chosen in the corresponding T1-weighted
images such that the smallest voxel did not contain any visible
interstitial tissue or fat, while the largest voxel was close to the
subcutaneous fat layer [16]. The calculation was performed
in the Java-based magnetic resonance user interface (jMRUI)
software package.
2.5. Statistics. Statistical analyses were performed using SPSS
18.0 software. The data are presented as the mean ± stan-
dard deviation (25th and 75th percentiles) for continuous
variables. Continuous variables with normal distribution
were compared by ANOVA and those without a normal
distribution were compared by the Kruskal-Wallis H test, if
unpaired, and the Mann-Whitney U test, if paired. Correla-
tion coefficients were analysed using Pearson’s (normally dis-
tributed data) or Spearman’s correlation (data not normally
distributed).
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Table 1: Clinical and biochemical characteristics.
NGT IGT T2DM P value
Sex (male/female) 17/12 7/10 6/7 0.484
Age (year) 47.62 ± 8.48 53.24 ± 6.55 50.92 ± 7.32 0.060
BMI (kg/m2) 25.14 ± 3.26 25.92 ± 2.96 26.39 ± 2.76 0.441
WHR 0.89 ± 0.07 0.89 ± 0.05 0.94 ± 0.07†‡ 0.036
SBP (mmHg) 117.45 ± 11.22 123.24 ± 15.77 124.69 ± 14.10 0.181
DBP (mmHg) 74.00 ± 9.17 74.94 ± 8.83 77.85 ± 10.21 0.468
FPG (mmol/L) 5.02 ± 0.45 5.09 ± 0.36 7.48 ± 1.60†‡ 0.000
PG30min (mmol/L) 8.87 ± 1.66 10.22 ± 1.65† 13.58 ± 2.22†‡ 0.000
PG2 h (mmol/L) 5.53 ± 1.00 8.97 ± 0.95† 15.66 ± 2.89†‡ 0.000
HBA1c (%) 5.52 ± 0.53 6.06 ± 0.30† 7.28 ± 1.23†‡ 0.000
CHOL (mmol/L) 5.12 ± 0.96 6.04 ± 1.02† 5.41 ± 1.07 0.014
TG (mmol/L) 1.19 (0.60–1.75) 1.57 (1.27–1.95) 2.03 (1.44–3.70)† 0.002
HDL-c (mmol/L) 1.26 (1.05–1.52) 1.27 (1.07–1.36) 1.05 (0.93–1.26) 0.074
LDL-c (mmol/L) 3.31 ± 0.91 4.37 ± 1.00† 3.75 ± 0.96 0.002
eGFR 102.18 ± 24.11 98.08 ± 13.15 98.79 ± 22.00 0.785
(mL/min × 1.73m2)
ALT (U/L) 19.00 (14.00–25.00) 21.00 (19.00–24.00) 39.50 (27.00–48.00)†‡ 0.003
AST (U/L) 20.00 (19.00–23.00) 21.00 (19.00–27.00) 28.50 (17.00–33.00) 0.102
GGT (U/L) 23.00 (20.00–35.00) 28.00 (20.00–40.00) 49.00 (34.00–83.00)† 0.003
Data are presented as the mean ± SD or median (25th–75th). †NGT versus IGT and T2DM 𝑃 < 0.05, ‡IGT versus T2DM 𝑃 < 0.05. BMI: body mass index,
WHR: waist-to-hip ratio, SBP: systolic blood pressure, DBP: diastolic blood pressure, FPG: fasting plasma glucose, PG30min: 30min plasma glucose, PG2 h:
2 h plasma glucose, HBA1c: hemoglobin A1c, CHOL: total cholesterol, TG: triglyceride, HDL-c: high-density lipoprotein, LDL-c: low-density lipoprotein, ALT:
alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma-glutamyl transpeptidase, and eGFR: estimated glomerular filtration rate.
Table 2: Insulin sensitivity and resistance.
NGT IGT T2DM 𝑃 value
𝑀 value
(mg/kg/min) 7.96 ± 2.54 5.93 ± 1.97
† 4.83 ± 2.80† 0.001
HOMA-IR 1.28 (0.97–1.50) 1.98 (0.93–2.55) 3.14 (2.03–3.32)† 0.001
HOMA-𝛽 79.70 (61.05–106.25) 122.86 (68.75–148.00) 69.32 (47.80–108.89) 0.233
IAI 0.03 (0.03–0.05) 0.02 (0.02–0.05) 0.01 (0.01–0.02)† 0.001
QUICK 0.37 (0.36–0.39) 0.34 (0.33–0.39) 0.32 (0.32–0.34)† 0.001
Data are presented as the mean ± SD or median (25th–75th). †NGT versus IGT and T2DM 𝑃 < 0.05.𝑀 value: Matsuda value calculated by hyperinsulinemic-
euglycemic clamp, HOMA-IR: homeostasis assessment insulin resistance, HOMA-𝛽: homeostasis assessment-𝛽, IAI: insulin activation indices, and QUICK:
quantitative insulin sensitivity check index.
3. Results
3.1. Characteristics of Study Participants. Baseline character-
istics of participants (shown in Table 1) had no differences
between the groups in terms of sex distribution, age, BMI,
HDL-c, GFR, AST, and blood pressure. Compared with those
with NGT, participants with T2DM and IGT had higher
blood glucose and HBA1c (𝑃 value < 0.05). Participants with
IGT had higher CHOL and LDL-c compared with those with
NGT (𝑃 value < 0.05), whereas participants with T2DM had
higher TG levels compared to those with NGT (𝑃 value <
0.05).
3.2. M Value, 𝛽 Cell Function, and Insulin Sensitivity. The
insulin sensitivity variables are listed in Table 2. During
the insulin clamp, plasma glucose and insulin levels were
kept at a steady-state. The 𝑀 value in participants with
NGT was significantly higher in those with IGT and T2DM
(𝑃 = 0.001). IGT and T2DM participants were more insulin
resistant compared to NGT participants as measured by
HOMA-IR (𝑃 value = 0.001). The IAI and QUICK values of
participants with T2DM were significantly lower than those
with NGT (𝑃 value = 0.05).
3.3. Body Fat Composition, Hepatocellular Lipid Content, and
Skeletal Muscle Fat Content (IMCL and EMCL). The hepato-
cellular lipid content ofNGT significantly lower than IGT and
T2DM participants, and the HCL of IGT significantly lower
than T2DM (𝑃 value < 0.05, results were presented at Table 3,
Figure 1(a) (𝑀 value), and Figure 1(b) (HCL)). The NGT
participants with lowest BFR and FM index were compared
with IGT and T2DM participants (𝑃 value < 0.05). Those
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Table 3: Body fat composition, HCL, and skeletal muscle fat content.
NGT IGT T2DM P value
BFR (%) 25.22 ± 6.19 31.42 ± 6.47† 30.63 ± 9.54† 0.010
FM index 6.45 ± 2.14 8.24 ± 2.29† 8.28 ± 3.15† 0.022
LM index 18.77 ± 2.15 17.75 ± 2.20 18.11 ± 1.50 0.253
HCL (%) 7.39 ± 3.71 12.27 ± 7.73† 17.37 ± 5.60†‡ 0.000
IMCL (sol) 7.88 (6.10–10.12) 8.25 (7.04–10.35) 10.70 (9.10–12.25) 0.208
(mmol/kg)
EMCL (sol) 17.54 (12.32–25.47) 18.62 (10.99–27.41) 22.84 (14.64–44.05) 0.754
(mmol/kg)
IMCL (ta) 1.74 (1.19–2.55) 2.52 (1.57–3.78) 5.20 (2.89–5.28)† 0.025
(mmol/kg)
EMCL (ta) 4.91 (2.56–9.59) 7.82 (3.93–11.01) 5.46 (2.85–9.48) 0.360
(mmol/kg)
Data are presented as the mean ± SD or median (25th–75th). †NGT versus IGT and T2DM 𝑃 < 0.05, ‡IGT versus T2DM 𝑃 < 0.05. BFR: body fat ratio, FM
index: fat mass index, and LM index: lean mass index; hepatocellular lipid content (HCL), intramyocellular lipid (IMCL), and extramyocellular lipid (EMCL)














































Figure 1:The (a) insulin sensitivity (𝑀 value) and (b) hepatocellular lipid content in different glucose tolerance status. ∗ refers to the 𝑃 value
of comparison between groups which is less than 0.05.
with T2DM had the highest IMCL (ta) (𝑃 value = 0.025).The
IMCL (sol), EMCL (sol), and EMCL (ta) were similar across
the groups.
3.4. Correlation Analyses. The 𝑀 value correlated signifi-
cantly with HCL (𝑃 value = 0.001), IMCL (sol) (𝑃 value
= 0.002), IMCL (ta) (𝑃 value = 0.001), and BFR (𝑃 value
= 0.002). Conversely, there was no significant relationship
between𝑀 value and EMCL (sol) or EMCL (ta) (𝑃 value >
0.05). After adjusting age, sex, and BMI, the correlation of
HCL (𝑃 value = 0.001) and IMCL (ta) (𝑃 value = 0.028) with
𝑀 value remains significant. See results at Table 4.
3.5. Stepwise Linear Regression Analysis. To investigate which
of the fat compartments were the strongest determinants of
insulin sensitivity, the stepwise linear regression analysis of
HCL and skeletal muscle fat content with𝑀 value was per-
formed after adjusting age, sex, and BMI. HCL (standardized
𝛽 = −0.416; 𝑃 value = 0.001) was independently associated
with 𝑀 value, but no statistically significant relationships
were observed for IMCL and EMCL.
4. Discussion
In T2DM, insulin resistance occurs in different organs,
including adipose tissues, liver, and skeletal muscles [17].
Our results state that the HCL and BFR were significantly
increased in participants with IGT andT2DMcomparedwith
NGT.The IMCL (ta) of T2DM participants were higher than
NGT subjects. Therefore, individuals with glucose impair-
ment had greater fat accumulation in the liver and skeletal
muscles.
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Table 4: Association of𝑀 value with variables.
Unadjusted Adjusting sex, age, andBMI
𝑟 𝑃 value 𝑟 𝑃 value
BMI −0.649 0.000
WHR −0.377 0.003 −0.273 0.058
SBP −0.299 0.021 −0.294 0.041
DBP −0.328 0.011 −0.281 0.050
FPG −0.341 0.008 −0.211 0.130
PG30min −0.410 0.001 −0.381 0.005
PG2 h −0.498 0.000 −0.473 0.000
HBA1c −0.357 0.005 −0.242 0.081
CHOL −0.181 0.171 −0.066 0.640
TG −0.524 0.000 −0.508 0.000
HDL-c 0.451 0.000 0.501 0.000
LDL-c −0.250 0.056 −0.177 0.205
GFR −0.041 0.758 0.113 0.419
ALT −0.469 0.000 −0.365 0.007
AST −0.296 0.023 −0.189 0.176
GGT −0.512 0.000 −0.450 0.001
HOMA-IR −0.720 0.000 −0.412 0.002
HOMA-𝛽 −0.370 0.004 −0.148 0.278
IAI 0.720 0.000 0.067 0.624
QUICK 0.721 0.000 0.211 0.119
BFR −0.404 0.002 −0.151 0.266
FM index −0.571 0.000 0.030 0.828
LM index −0.165 0.213 0.155 0.256
HCL −0.789 0.000 −0.613 0.000
IMCL (sol) −0.427 0.002 −0.084 0.577
EMCL (sol) −0.115 0.430 0.057 0.708
IMCL (ta) −0.419 0.002 −0.323 0.028
EMCL (ta) −0.067 0.644 0.074 0.624
Correlation coefficients were analysed using Pearson’s (normally distributed
data) or Spearman’s correlation (data not normally distributed).
Lipids may accumulate in nonadipose tissues, such as
muscles, when the adipose tissues are saturated, thereby
causing hepatic and muscle insulin resistance [18]. Meshkani
and Adeli [2] showed that hepatic insulin resistance leads
to the metabolic syndrome and promotes progression to
cardiovascular diseases. Our study showed that HCL, IMCL
(sol), IMCL (ta), and BFR correlate inversely with the 𝑀
value, but there was no relationship between 𝑀 value and
EMCL. Linear regression analysis demonstrated that HCL
is an independent risk factor for dyslipidemia and insulin
resistance.
Our findings, consistentwith themajority of data, showed
that liver fat is the strongest determinant of insulin sensitivity
among fat compartments in human [19–22]. Kirchhoff et al.
[19] state that insulin sensitivity correlates inversely with hep-
atocellular lipid content and intramyocellular fat of tibialis
anterior muscle, and the study of Kotronen et al. [20] showed
that fat accumulation in the liver rather than in skeletal
muscle is associatedwith features ofmetabolic syndrome, and
there was no differences in the IMCL content in those with
or without the syndrome. While the data of Krssak et al. [23]
showed an inverse correlation between intramyocellular lipid
content and𝑀 value, IMCL is a good indicator ofwhole-body
insulin sensitivity in nondiabetic, nonobese humans.
The discrepancy of studies may be due to methodology
differences. Some studies measured the peak area while
others measured peak intensity of muscle fat. On measuring
liver fat, the hepatic iron metabolism is an important player
in the development of systemic insulin resistance [24]. Most
of the studies did not measure the hepatic iron load and this
may possibly affect the results.The resultsmay also be affected
by the exercises or time of measured muscle lipid content
[10, 25].
There are several limitations of this study. First, the lack
of use of a glucose tracer in the hyperinsulinemic-euglycemic
clamp limits the determination of hepatic glucose produc-
tion rates. Hyperinsulinemic-euglycemic clamp was used
to calculate the glucose infusion rates, which is a measure
of whole-body glucose disposal and not glucose utilization
rates since it does not take into account the hepatic glucose
production rates [26]. Second, the sample size was relatively
small. Third, we did not include individuals with IFG.
In conclusion, as glucose level increased there was the
accumulation of fat deposition. Compared to NGT individu-
als, IGT and T2DMparticipants have higher HCL (𝑃 < 0.05),
and the IMCL (ta) of T2DM is significantly higher than NGT
(𝑃 < 0.05). Liver fat deposition happens earlier than skeletal
muscle fat deposition. Hepatocellular lipid content plays a
predominant role in determination of insulin sensitivity and
may be used in evaluating the risk of developing T2DM as a
noninvasive marker of insulin sensitivity index.
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